CTSB and cancer: For example, cancer-activated doxorubicin prodrug nanoparticles (CAP-NPs) can specifically release cytotoxic doxorubicin when targeting cathepsin B-overexpressing cancer cells, which significantly reduces systemic adverse effects as well as greatly increases the rate of tumor regression in combination with ICIs [190].